

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1618
RIGASSI-DIETRICH, PETRA GISELA ET AL. EXAMINER: VU, JAKE MINH
INTERNATIONAL APPLICATION NO: PCT/EP2005/002798
FILED: MARCH 16, 2005
U.S. APPLICATION NO: 10/590398
35 USC §371 DATE: AUGUST 23, 2006
FOR: GALENIC FORMULATIONS OF ORGANIC COMPOUNDS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed January 17, 2007.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to
Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R.
§1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO/SB/08A/B.


☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A/B form(s).

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9587

Date: 8/17/11

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864